相关实验视频
Updated: Jul 22, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
人口药理动力学建模和随机模拟以支持小儿用皮马万塞林剂量选择
Mona Darwish1, Dragana Bugarski-Kirola2, David Jaworowicz3
1Acadia Pharmaceuticals Inc., Princeton, NJ, USA.
皮马万塞林20毫克和34毫克的剂量在5-17岁的儿科患者中达到与成年人34毫克相似的稳定状态暴露. 这表明帕金森病精神病和其他神经精神疾病的治疗结果相似.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 儿科精神病学 儿科精神病学
背景情况:
- 皮马万塞林是一种选择性的血清素5-HT2A受体逆agonist/antagonist.
- 成年人每天34毫克的皮马万塞林的疗效和安全性已在帕金森病精神病和其他神经精神疾病中得到证实.
- 儿科用剂量需要评估,以匹配成人暴露水平.
研究的目的:
- 确定皮马万塞林剂量,使儿科暴露与成年人暴露相当,每日34毫克.
- 为潜在的儿科治疗方案提供信息,以治疗帕金森病,精神病等疾病.
主要方法:
- 使用来自13项临床研究的数据,包括青少年 (13-17岁) 的人口药理动力学建模.
- 随机模拟用于预测虚拟儿科患者 (5-17岁) 的稳定状态暴露 (AUC,Cmax).
- 针对不同年龄和体重层的模拟儿科暴露与34毫克的模拟成年 (18-49岁) 暴露的比较.
主要成果:
- 模拟成人的平均AUC:47.41-54.73 ng·d/mL;平均Cmax:41.13-50.07 ng/mL在34毫克.
- 皮马万塞林34毫克在儿科患者 (10-17岁) 中显示平均Cmax为56.54ng/mL,类似于成年人.
- 在儿科患者 (5-9岁) 和体重为14-25公斤的患者中,皮马万塞林20毫克的平均Cmax值分别为45.30 ng/mL和49.18 ng/mL,接近成人Cmax.
结论:
- 在10-17岁的儿科患者中,每天34毫克的皮马万塞林会导致与成年人相比的暴露.
- 在5-9岁的儿科患者中,每天20毫克的皮马万塞林达到与成年人34毫克剂量相似的暴露.
- 这些发现支持皮马万塞林在儿童群体中对相关神经精神疾病的潜在使用.
更多相关视频
07:41Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
Published on: June 5, 2017
13:54A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
Published on: August 18, 2023
相关概念视频
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Analysis of Population Pharmacokinetic Data
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...